Actively Recruiting

Phase Not Applicable
Age: 18Years - 70Years
FEMALE
ID04967976

A Prospective Randomized and Controlled Study of Efficacy and Safety of TiLOOP Bra Mesh in Patients With Expander-Implant Breast Reconstruction

Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2021-07-20

300

Participants Needed

6

Research Sites

156 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the use of TiLOOP4 Bra mesh in patients undergoing expander-implant breast reconstruction after breast cancer surgery. This is the first prospective randomized and controlled study designed to assess the safety and effectiveness of incorporating TiLOOP Bra mesh with tissue expanders. The goal is to see if this mesh can reduce capsular contracture rates, improve the efficiency of tissue expansion, and provide better aesthetic results compared to reconstruction without mesh. Participants will be randomly assigned to one of two groups: one receiving tissue expander-implant reconstruction with TiLOOP Bra mesh placed sub-pectorally immediately after nipple or skin-sparing mastectomy, and the other receiving tissue expander-implant reconstruction without the mesh, where the expander is placed sub-pectorally and covered by muscle or fascia. The study includes a triple masking design to reduce bias. During the study, participants will be monitored for complications up to 24 months post-surgery and for expansion efficiency over about one year. Additional assessments include the number of revision surgeries, aesthetic outcomes evaluated by the Harris score and Breast-Q questionnaire, psychological evaluations, total treatment cost, and occurrences of deep venous thrombosis or infections. The study spans from tissue expander implantation through expander exchange and follow-up, with careful safety and outcome monitoring throughout.

CONDITIONS

Brief Title

Breast Mesh Used in Two-staged Breast Reconstruction

Who Can Participate

Age: 18Years - 70Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with breast cancer
  • Age more than 18 years and up to 70 years
  • Karnofsky Performance Status (KPS) larger than 80
  • No clinical or imaging evidence of distant metastasis
  • Body mass index (BMI) less than 35 kg/m2
  • Patients with no or mild breast sagging (ptosis)
  • No severe deficiency in blood, heart, immune system, liver, or kidney function
  • Mental health patient
Not Eligible

You will not qualify if you...

  • Patients with distant metastasis of breast cancer or local recurrence
  • Past radiation treatment to the same breast or chest wall
  • Inflammatory breast cancer or stage IV breast cancer
  • History of severe allergies or specific medical conditions
  • Mental illness
  • Drug or alcohol abuse
  • Pregnancy, breastfeeding, or becoming pregnant during the trial
  • Deemed ineligible by researchers based on study requirements

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Surgery and Immediate Post-operative Care

Duration - Day of surgery and hospital stay period

Participants undergo two-staged breast reconstruction surgery with or without TiLoop Bra mesh immediately after nipple/skin-sparing mastectomy. The tissue expander is placed sub-pectorally during the first stage of reconstruction.

1 surgical visit and immediate post-operative hospital care

Post-operative Follow-up

Duration - Up to 24 months after surgery

Participants are followed up to monitor complication rates, expansion efficiency, and other outcomes after surgery and expander implantation.

Approximately monthly visits during the first year and less frequent visits thereafter up to 24 months

Trial Site Locations

Total: 6 locations

1

MD Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

2

Gansu Provincial Cancer Hospital

Lanzhou, Gansu, China

Actively Recruiting

3

Jilin Cancer Hospital

Ch’ang-ch’un, Jilin, China

Actively Recruiting

4

Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, China, 300060

Actively Recruiting

5

Zhejiang Provincial People's Hospital

Hangzhou, Zhejiang, China

Actively Recruiting

6

Technical University of Munich

Munich, Germany

Actively Recruiting

Loading map...

Research Team

J

Jian Yin

B

Bowen Ding

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Investigating The Role of Key Non-coding RNA(s) in Breast Ca...

Breast Cancer

Actively Recruiting

1 location

18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Bre...

Breast Cancer

Actively Recruiting

1 location

Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for...

Clear Cell Renal Cell Cancer (ccRCC)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here